The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
Explore this paper's citation graph
Summary
The hypothesis that a high score predicts benefit from TMZ treatment for patients with IDHmt LGG, regardless of the 1p/19q status is supported, and may identify patients who benefit from first-line treatment with TMZ, to defer RT for long-term preservation of cognitive function and quality of life.
- Type
- article
- Published
- 2018-01-24
- Cited by
- 81
- References
- 52
- Access
- Open access
- OpenAlex
- https://openalex.org/W2787702713
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4169116
Keywords
Temozolomide, Isocitrate dehydrogenase, O-6-methylguanine-DNA methyltransferase, Glioma, DNA methylation
References
- Lynch Syndrome Genes
- Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays
- A Unifying Tool for Linear Multivariate Statistical Methods: The RV‐Coefficient
- The ade4 package - I : One-table methods
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- Genetic and epigenetic characterization of low‐grade gliomas reveals frequent methylation of the MLH3 gene
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
- Predictive biomarkers for cancer therapy with PARP inhibitors
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
- Conditional nuclear localization of hMLH3 suggests a minor activity in mismatch repair and supports its role as a low-risk gene in HNPCC.
- Mutational landscape and clonal architecture in grade II and III gliomas
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair.
- The ACT (STATIS method)
- Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma
- Graphs, Causality, and Structural Equation Models
- Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis
- A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Cited by
- Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?
- What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?
- Iterative Surgical Resections of Diffuse Glioma With Awake Mapping: How to Deal With Cortical Plasticity and Connectomal Constraints?
- Long noncoding RNA HOXB13‐AS1 regulates HOXB13 gene methylation by interacting with EZH2 in glioma
- Paradoxes of evidence-based medicine in lower-grade glioma
- Molecular classification of adult gliomas: recent advances and future perspectives
- PAXX Participates in Base Excision Repair via Interacting with Pol β and Contributes to TMZ Resistance in Glioma Cells
- MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
- Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases.
- Updates in prognostic markers for gliomas.
- Epidemiology and Molecular Epidemiology.
- Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases
- MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
- Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network
- New developments and new dilemmas in lower-grade gliomas.
- The landscape of postsurgical recurrence patterns in diffuse low-grade gliomas.
- Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients
- Casein Kinase 2 Interacting Protein-1 Suppresses Glioma Cell Proliferation via Regulating the AKT/GSK3β/β-Catenin Pathway
- Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
- A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
Related papers
- Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma
- Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase‐1
- High‐grade gliomas with isocitrate dehydrogenase wild‐type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis
- Temozolomide in aggressive pituitary adenomas and carcinomas
- Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6 -methylguanine- DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen
- O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
- O6-Methylguanine DNA methyltransferase protein expression and TMZ resistance in patients with glioblastoma multiforme
- Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide